Nang Kuang Pharmaceutical Co (TPE:1752) Research & Development: NT$171 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1752 Nang Kuang Pharmaceutical Co Ltd TPE:1752
88 GF Score
Price NT$31.35
GF Value NT$46.62
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Nang Kuang Pharmaceutical Co Research & Development?

Nang Kuang Pharmaceutical Co TPE:1752 -1.10% 88 Research & Development is NT$171 Mil as of Dec. 2025. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nang Kuang Pharmaceutical Co's Research & Development for the three months ended in Dec. 2025 was NT$38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$171 Mil.

Nang Kuang Pharmaceutical Co  (TPE:1752) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nang Kuang Pharmaceutical Co Research & Development Related Terms

Nang Kuang Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Nang Kuang Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nang Kuang Pharmaceutical Co Research & Development Chart

Nang Kuang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 133.97 143.81 164.11 169.36 170.58

Nang Kuang Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.72 42.04 48.98 41.35 38.21
TPE:1752
88GF Score
Nang Kuang Pharmaceutical Co Ltd TPE:1752
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nang Kuang Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$171 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$171 Mil mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Research & Development of NT$171 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Nang Kuang Pharmaceutical Co and its competitors.
Is Nang Kuang Pharmaceutical Co's Research & Development too high?
Nang Kuang Pharmaceutical Co's current Research & Development is NT$171 Mil. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Research & Development compare to ISRG and BDX?
Nang Kuang Pharmaceutical Co's Research & Development of NT$171 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nang Kuang Pharmaceutical Co and its competitors. Nang Kuang Pharmaceutical Co's current Research & Development is NT$171 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current Research & Development is NT$171 Mil. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Research & Development is NT$171 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?

Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62. GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for TPE:1752:

  • Research & Development: NT$171 Mil
  • GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nang Kuang Pharmaceutical Co Business Description

Address Section 8, Civic Boulevard, 5th Floor, No. 205, Nangang District, Taipei, TWN, 115
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score

Get the complete analysis for TPE:1752

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.35
Price
NT$46.62
GF Value